Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH

Current Urology Reports

Volumn 11, Issue 4, 2010, Pages 254-260

  Gomelsky, Alex ^a   Dmochowski, Roger R ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Benign prostatic hypertrophy; Erectile dysfunction; Lower urinary tract symptoms; Phosphodiesterase type 5 inhibitors

Indexed keywords

ALFUZOSIN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

BLADDER FUNCTION; BLADDER NECK STENOSIS; CLINICAL TRIAL; COMORBIDITY; DETRUSOR MUSCLE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; NONHUMAN; PREVALENCE; PROSTATE HYPERTROPHY; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URODYNAMICS; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATISM;

CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; URODYNAMICS; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 77956011764     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0122-8     Document Type: Review

References (50)

1. Berry SJ, Coffey DS, Walsh PC, et al.: The development of benign prostatic hyperplasia with age. J Urol 1984, 132:474-479.
2. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338:469-471.
3. Baine WB, Yu W, Summe JP, et al.: Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from1991 to 1995. J Urol 1998, 160:816-820.
4. Roehrborn CG, McConnell JD, Barry MJ, et al.: Guidelines on the Management of Benign Prostatic Hyperplasia. Linthicum, MD: American Urological Association, Education and Research, Inc; 2003.
5. Sciarra A: Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies. Eur Urol 2007, 51:1485-1487.
6. Mouli S, McVary KT: PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis 2009, 12:316-324. This is a detailed review of proposed mechanisms of action of PDE5 inhibitors for LUTS.
7. Dmochowski R, Roehrborn C, Klise S, et al.: Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo-controlled 12-week clinical trial. J Urol 2010, 183:1092-1097. This is an initial urodynamic study revealing no negative impact on bladder function after treatment with tadalafil.
8. Feldman H, Goldstein I, Hatzichristou D, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54-61.
9. Rosen RC, Giuliano F, Carson CC: Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005, 47:824-837.
10. Rosen R, Altwein J, Boyle P, et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003, 44:637-649.
11. Rajfer J, Aronson WJ, Bush PA, et al.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326:90-94.
12. Andersson KE: Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003, 170:S6-S14.
13. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP: Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000, 184:409-420.
14. Corbin JD: Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004, 16:S4-S7.
15. Andersson KE: Pharmacology of lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev 1993, 45:253-308.
16. Smet PJ, Jonavicius J, Marshall VR, de Vente J: Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996, 71:337-348.
17. Gillespie JI, Markerink-van Ittersum M, de Vente J: Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005, 321:341-351.
18. Hedlund P, Ekstrom P, Larsson B, et al.: Heme oxygenase and NO synthase in the human prostate-relation to adrenergic, cholinergic and peptide containing nerves. J Auton Nerv Syst 1997, 63:115-126.
19. Waldkirch E, Ückert S, Langnäse K, et al.: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007, 52:495-502.
20. Bloch W, Klotz T, Loch C, et al.: Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997, 33:1-8.
21. Klotz T, Mathers MJ, Bloch W, et al.: Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999, 31:335-341.
22. Tinel H, Stelte-Ludwig B, HÜtter J, Sandner P: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006, 98:1259-1263
23. Filippi S, Morelli A, Sandner P, et al.: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148:1019-1029.
24. Uckert S, Kuthe A, Jonas U, Stief CG: Characterization and functional reference of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001, 166:2484-2490.
25. Uckert S, Hedlund P, Oelke M, et al.: Immunohistochemical presence of phosphodiesterase 11A in the human prostate. J Urol 2004, 171:352.
26. Ückert S, Hedlund P, Andersson KE, et al.: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future? Eur Urol 2006, 50:1194-1207.
27. Lindberg C, Nishtman D, Malmqvist UP, et al.: Increased expression of RhoA in prostates of spontaneously hypertensive rats. J Urol 2004, 171(Suppl):348, A1320.
28. Bing W, Chang S, Hypolite JA, et al.: Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003, 285:F990-F997.
29. Chang S, Hypolite JA, Zderic SA, et al.: Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005, 289:R1124-R1130.
30. Chang S, Hypolite JA, Changolkar A, et al.: Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003, 15:53-62.
31. Seko T, Ito M, Kureishi Y, et al: Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003, 92:411-418.
32. Rees RW, Foxwell NA, Ralph DJ, et al.: Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003, 170:2517-2522.
33. Rajasekaran M, White S, Baquir A, Wilkes N: Rho-kinase inhibition improves erectile function in aging male Brown Norway rats. J Androl 2005, 26:182-188.
34. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415-1428.
35. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998, 1:157-162.
36. Hammarsten J, Hogstedt B: Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999, 8:29-36.
37. McVary KT, Razzaq A, Lee C, et al.: Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994, 51:99-107.
38. Rahman NU, Phonsombat S, Bochinski D, et al.: An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidemic rat. BJU Int 2007, 100:658-663.
39. Hale TM, Okabe H, Bushfield TL, et al.: Recovery of erectile function after brief aggressive anti-hypertensive therapy. J Urol 2002, 168:348-354.
40. McVary KT, Rademaker A, Lloyd GL, Gann P: Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005, 174:1327-1333.
41. Tarcan T, Azadzoi KM, Siroky MB, et al.: Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J Urol 1998, 82:26-33.
42. Ponholzer A, Temml C, Wehrberger C, et al.: The association between LUTS and vascular risk factors in both sexes. Eur Urol 2006, 50:581-586.
43. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ: Atherosclerosisinduced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol 1999, 161:1626-1635.
44. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB: Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003, 170:659-663.
45. McVary KT, Roehrborn CG, Kaminetsky JC, et al.: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-1407.
46. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L: Tadalafil administered once daily for lower urinary tract symp-toms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008, 180:1228-1234.
47. McVary KT, Monnig W, Camps JL Jr, et al.: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071-1077.
48. Stief CG, Porst H, Neuser D, et al.: A randomised, placebocontrolled study to assess the efficacy of twice-daily Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53:1236-1244.
49. Kaplan SA, Gonzales RR, Te AE: Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51:1717-1723.
50. Gacci M, Del Popolo G, Macchiarella A, et al.: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007, 178:2040-2043.